The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites.
about
Plasmodium vivax DBP binding to Aotus nancymaae erythrocytes is Duffy antigen dependentCodon usage: nature's roadmap to expression and folding of proteinsSuccessful vaccines for naturally occurring protozoal diseases of animals should guide human vaccine research. A review of protozoal vaccines and their designsPreparative purification of recombinant proteins: current status and future trendsImmunogenicity of self-associated aggregates and chemically cross-linked conjugates of the 42 kDa Plasmodium falciparum merozoite surface protein-1Immunization with pre-erythrocytic antigen CelTOS from Plasmodium falciparum elicits cross-species protection against heterologous challenge with Plasmodium bergheiAcquired antibody responses against Plasmodium vivax infection vary with host genotype for duffy antigen receptor for chemokines (DARC)Heterologous protein expression is enhanced by harmonizing the codon usage frequencies of the target gene with those of the expression host.Histidine affinity tags affect MSP1(42) structural stability and immunodominance in mice.Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan children.Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial.Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responsesAntibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adultsBlood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya.A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coliIn vitro growth-inhibitory activity and malaria risk in a cohort study in maliAllele specificity of gamma interferon responses to the carboxyl-terminal region of Plasmodium falciparum merozoite surface protein 1 by Kenyan adults with naturally acquired immunity to malaria.Antibodies against multiple merozoite surface antigens of the human malaria parasite Plasmodium falciparum inhibit parasite maturation and red blood cell invasionStrategies for designing and monitoring malaria vaccines targeting diverse antigensTransplacentally transferred functional antibodies against Plasmodium falciparum decrease with age.A malaria vaccine based on the polymorphic block 2 region of MSP-1 that elicits a broad serotype-spanning immune responseMarked variation in MSP-119 antibody responses to malaria in western Kenyan highlands.Analysis of antibodies directed against merozoite surface protein 1 of the human malaria parasite Plasmodium falciparum.IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys.Plasmodium falciparum: immunization with MSP1-42 induced non-inhibitory antibodies that have no blocking activities but enhanced the potency of inhibitory anti-MSP1-42 antibodies.Head-to-Head Comparison of Soluble vs. Qβ VLP Circumsporozoite Protein Vaccines Reveals Selective Enhancement of NANP Repeat Responses.Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1.Malaria vaccines in development.Impact of pre-existing MSP1(42)-allele specific immunity on potency of an erythrocytic Plasmodium falciparum vaccine.Variation in exposure to Anopheles gambiae salivary gland peptide (gSG6-P1) across different malaria transmission settings in the western Kenya highlands.Contrasting Patterns of Serologic and Functional Antibody Dynamics to Plasmodium falciparum Antigens in a Kenyan Birth CohortResults from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells.Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infectionProgress and prospects for blood-stage malaria vaccinesA chimeric Plasmodium falciparum merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodiesTemporal stability of naturally acquired immunity to Merozoite Surface Protein-1 in Kenyan adults.Immunogenicity of bacterial-expressed recombinant Plasmodium knowlesi merozoite surface protein-142 (MSP-142).
P2860
Q24596355-9952B369-7CD6-44A7-B3B0-3278A22757CFQ24605121-331A2470-D3F2-4831-B9A9-E4DD34141251Q26825650-6BBFE7B7-90B0-4099-995A-E4DC0F613345Q27008176-CF9BF431-C626-4B67-9882-3A0FD8431B87Q28484081-5473A8C4-80E3-453E-AF88-98E14979FCAAQ28749621-8BCCB1A7-40C4-45A6-A1AE-125A043BCC8DQ28750566-64C2AEBB-7ED5-451E-ADFD-08DB7E034A1DQ30369393-94EFFC48-C847-49A5-9D3F-5A23F066C7C6Q30409373-56AE4CC5-F83E-4673-ACD0-B6ED5E2F6B32Q33264521-1259156A-31AF-4B81-B7B2-5A2A68F7354DQ33264523-C6BC0574-CA1B-405A-AF15-1EF9653935F4Q33356029-303E6743-572C-48AF-A772-37196BA1C1D4Q33380213-EC22EB6D-E03E-4E81-8028-C181FAB33779Q33415066-86245244-A795-4F29-BE85-D53BE214E349Q33485233-3C9DF027-C65A-401B-B6E9-337EF75239F1Q33613892-6E077B76-4E61-4C54-A547-19E295594AE6Q33653151-AAB432D9-A17D-4A3A-B2C3-1E281FFC6558Q33761687-092D5EC7-1225-4E7B-B8E2-952CA4478514Q33959038-15A73F19-7674-4AF4-A9F0-52324C424FF7Q34060022-A7DE0C19-E276-43C5-9722-4CDB5CD0F5A6Q34071439-23B1758C-CD3F-41DB-B30B-C6BC8C7AA121Q34180495-4675213D-1824-4238-8B67-B40D2791E00EQ34334187-921BC48E-8FE7-4028-B4C6-0C36E98202C9Q34400813-6AFF289A-4883-4DDB-8858-9C2E919B0CC8Q34975629-7AB33DAF-7627-4969-8AD6-0F85CF4C889AQ34978590-EB07F8C0-2FDE-4F7E-8D53-7C2F72C14DC8Q35762375-92A4AA0D-3B04-42B9-8687-55B10F300AE8Q35841913-DF8EF98C-7694-4C74-89B9-7C65F02F03E4Q36114395-D045C616-406B-4D0D-B33E-3A642A5AEE12Q36219634-185E169E-B308-4723-B8C8-E032EBD23F9CQ36412687-5FA8C8CE-A6F7-4870-A4FA-CB3BA7A38A18Q36521143-4DD76256-1FB9-4F46-852E-D4A16463DF82Q36555103-87E6F821-EEB9-4C5A-81D6-300B583204E5Q36639261-82BC260A-054F-4A40-942A-B378EF620550Q36640081-DD0E8AD7-D4FC-4BE8-9EA5-CB258FA0BD28Q36903515-787C2009-8FD5-4FA3-AF8A-90AB98C2B05EQ37025030-BCD4F127-DCB7-448B-8B49-73CA152D243EQ37264673-0D1C3131-46A8-4B76-8002-09119BF9422BQ37285846-9E87BF9A-40F0-47F8-8605-9F1409B182B8Q37425845-1C2C1795-3838-4DC3-87F1-EBB5F22363F9
P2860
The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
The clinical-grade 42-kilodalt ...... erythrocytic-stage parasites.
@ast
The clinical-grade 42-kilodalt ...... erythrocytic-stage parasites.
@en
The clinical-grade 42-kilodalt ...... erythrocytic-stage parasites.
@nl
type
label
The clinical-grade 42-kilodalt ...... erythrocytic-stage parasites.
@ast
The clinical-grade 42-kilodalt ...... erythrocytic-stage parasites.
@en
The clinical-grade 42-kilodalt ...... erythrocytic-stage parasites.
@nl
prefLabel
The clinical-grade 42-kilodalt ...... erythrocytic-stage parasites.
@ast
The clinical-grade 42-kilodalt ...... erythrocytic-stage parasites.
@en
The clinical-grade 42-kilodalt ...... erythrocytic-stage parasites.
@nl
P2093
P2860
P1476
The clinical-grade 42-kilodalt ...... erythrocytic-stage parasites.
@en
P2093
Anthony A Holder
Autumn S Girouard
Carter L Diggs
Christian A Darko
Elke S Bergmann-Leitner
Evelina Angov
Jana S McBride
Jeffrey A Lyon
John W Barnwell
Stacy L Hitt
P2860
P304
P356
10.1128/IAI.73.1.287-297.2005
P407
P577
2005-01-01T00:00:00Z